组织因子通路抑制剂-2 (TFPI-2) - - 在癌症和转移中被低估的参与者
Marek Z Wojtukiewicz1,2, Marta Mysliwiec3, Anna Tokajuk4
1Department of Oncology, Medical University of Bialystok, 12 Ogrodowa, 15-027, Bialystok, Poland. mzwojtukiewicz@gmail.com.
组织因子通路抑制剂-2 (TFPI-2) 通过各种机制影响癌症转移. 重新激活TFPI-2可能为未来的癌症治疗开发提供了一个有希望的策略.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 凝血系统与癌症的进展和转移有关.
- 凝血在癌症中的作用的确切机制尚未完全理解.
- 组织因子通路抑制剂-2 (TFPI-2) 是一种具有潜在抗癌功能的蛋白酶抑制剂.
研究的目的:
- 为提供TFPI-2对癌症发展和转移的影响的最新概述.
- 探索TFPI-2在抑制瘤生长和扩散中的多方面的作用.
- 强调需要进一步研究TFPI-2的功能和治疗潜力.
主要方法:
- 文献综述和对TFPI-2现有研究的综合.
- 对TFPI-2与血栓级联相互作用的分析.
- 检查TFPI-2的与凝血无关的抗癌机制.
主要成果:
- TFPI-2通过稳定细胞外基质,促进细胞亡,抑制血管生成和调节细胞内信号来抑制癌症.
- 在各种瘤中观察到TFPI-2表达的下调,通常是通过促进物甲基化.
- TFPI-2与血栓级联的相互作用有助于其抗癌作用.
结论:
- TFPI-2表现出多种机制来抑制癌症的发展和转移.
- 需要进一步的研究,以充分阐明TFPI-2在癌症进展中的作用.
- 旨在调节或重新激活TFPI-2的策略是新型癌症治疗的有希望的途径.
更多相关视频
09:44Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior
Published on: June 13, 2016
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
相关概念视频
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle
Regulation of Angiogenesis and Blood Supply
The Tumor Microenvironment
Non-Canonical Wnt Signaling Pathways
